# Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

> **NCT00934518** · PHASE2 · WITHDRAWN · sponsor: **Milton S. Hershey Medical Center**

## Conditions studied

- Squamous Cell Cancer of the Head and Neck

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00934518
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-07
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate patient accrual
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934518, "Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00934518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*